Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.

about

Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review).

P2860

Q37701501-E04637CB-14B1-424E-AFBA-EE6BBCBFFEA9 Q39401616-35C094DF-2FE2-44B2-8ACB-C42B408FED61

P2860

Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.

Item

http://www.wikidata.org/entity/Q38357132

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Mutations in tyrosine kinase a ...... y in hematologic malignancies.

@en

type

Item

label

Mutations in tyrosine kinase a ...... y in hematologic malignancies.

@en

prefLabel

Mutations in tyrosine kinase a ...... y in hematologic malignancies.

@en

P1476

Mutations in tyrosine kinase a ...... py in hematologic malignancies

@en

P2093

Chan Zhao

http://www.w3.org/2001/XMLSchema#string

Haowen Xiao

http://www.w3.org/2001/XMLSchema#string

Li-Mengmeng Wang

http://www.w3.org/2001/XMLSchema#string

Ni Zhu

http://www.w3.org/2001/XMLSchema#string

Shan Fu

http://www.w3.org/2001/XMLSchema#string

P2860

Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis

The Hallmarks of Cancer

Cloning and expression of an inducible lymphoid-specific, protein tyrosine phosphatase (HePTPase)

Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73

PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin/E-cadherin complexes in cancer cells

An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis

FMS mutations in myelodysplastic, leukemic, and normal subjects

Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia

Leukemia-associated, constitutively active mutants of SHP2 protein tyrosine phosphatase inhibit NF1 transcriptional activation by the interferon consensus sequence binding protein

A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia

P304

659-673

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.14.280

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

He Huang

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25686120

http://www.w3.org/2001/XMLSchema#string

Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.

about

P2860

P2860

Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698